Nanomedicines

Izon, NZ

Design Considerations for Properties of Nanocarriers on the Disposition and Efficiency of Drug and Gene Delivery;

Targeting Cyclins and Cyclin-Dependent Kinases Involved in Cell Cycle Regulation by RNAi as a Potential Cancer Therapy;

Nanoparticle carriers to overcome biological barriers to siRNA delivery;

Magnetic targeting as a vehicle for delivery of nanomedicines;

Development of Theranostics – Imaging Considerations and Targeted Drug Delivery;

The Role of Imaging in Nanomedicine Development and Clinical Translation;

Anticancer agent-incorporating polymeric micelles: from bench to bedside;

Polymeric Nanoparticles and Cancer: Lessons Learnt from CRLX101;

Nanodelivery Strategies in Breast Cancer Chemotherapy;

Developing a Predictable Regulatory Path for Nanomedicines by Accurate and Objective Particle Measurement;

Nanomedicine: Promises and Challenges;

The Challenge of Regulating Nanomedicine: Key Issues;

Doxil® – The First FDA-Approved Nano-Drug: From Basics via CMC, Cell Culture and Animal Studies to Clinical Use